CA2336945C - Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate - Google Patents

Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate Download PDF

Info

Publication number
CA2336945C
CA2336945C CA002336945A CA2336945A CA2336945C CA 2336945 C CA2336945 C CA 2336945C CA 002336945 A CA002336945 A CA 002336945A CA 2336945 A CA2336945 A CA 2336945A CA 2336945 C CA2336945 C CA 2336945C
Authority
CA
Canada
Prior art keywords
formula
compound
day
pharmaceutical composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002336945A
Other languages
English (en)
French (fr)
Other versions
CA2336945A1 (en
Inventor
Stanislaw R. Burzynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2336945A1 publication Critical patent/CA2336945A1/en
Application granted granted Critical
Publication of CA2336945C publication Critical patent/CA2336945C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002336945A 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate Expired - Fee Related CA2336945C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/121,567 1998-07-23
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (2)

Publication Number Publication Date
CA2336945A1 CA2336945A1 (en) 2000-02-03
CA2336945C true CA2336945C (en) 2008-11-18

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002336945A Expired - Fee Related CA2336945C (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Country Status (20)

Country Link
US (2) US6258849B1 (OSRAM)
EP (1) EP1098643B1 (OSRAM)
JP (2) JP2002521329A (OSRAM)
KR (4) KR100399658B1 (OSRAM)
CN (3) CN100400039C (OSRAM)
AT (1) ATE257378T1 (OSRAM)
AU (1) AU759278B2 (OSRAM)
BR (1) BR9912356A (OSRAM)
CA (1) CA2336945C (OSRAM)
DE (1) DE69914084T2 (OSRAM)
DK (1) DK1098643T3 (OSRAM)
EA (1) EA004179B1 (OSRAM)
ES (1) ES2214866T3 (OSRAM)
ID (1) ID28160A (OSRAM)
IL (1) IL140848A (OSRAM)
NZ (1) NZ509244A (OSRAM)
PL (1) PL213698B1 (OSRAM)
PT (1) PT1098643E (OSRAM)
WO (1) WO2000004894A2 (OSRAM)
ZA (1) ZA200100622B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
JP2008508300A (ja) * 2004-07-28 2008-03-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌剤としての３−ブロモ−２−オキソプロピオン酸プロピルおよび誘導体
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
NZ609191A (en) 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
IL270413B (en) 2017-05-11 2022-08-01 Ocera Therapeutics Inc Processes of making l-ornithine phenylacetate
IL272422B2 (en) * 2017-06-12 2025-03-01 R Burzynski Stanislaw Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
CA2254772C (en) 1996-05-14 2004-01-27 Stanislaw R. Burzynski Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Also Published As

Publication number Publication date
US6258849B1 (en) 2001-07-10
DE69914084T2 (de) 2004-10-28
CN1605334A (zh) 2005-04-13
HK1037142A1 (en) 2002-02-01
ZA200100622B (en) 2002-06-26
EP1098643B1 (en) 2004-01-07
CN1191064C (zh) 2005-03-02
WO2000004894A2 (en) 2000-02-03
NZ509244A (en) 2004-02-27
EA200100168A1 (ru) 2001-08-27
KR20030027088A (ko) 2003-04-03
PT1098643E (pt) 2004-05-31
KR100417100B1 (ko) 2004-02-05
KR100414587B1 (ko) 2004-01-13
CN1319010A (zh) 2001-10-24
ID28160A (id) 2001-05-10
ES2214866T3 (es) 2004-09-16
BR9912356A (pt) 2001-04-17
JP2002521329A (ja) 2002-07-16
IL140848A0 (en) 2002-02-10
IL140848A (en) 2005-05-17
KR20030027087A (ko) 2003-04-03
DE69914084D1 (de) 2004-02-12
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
JP2011051993A (ja) 2011-03-17
KR100417101B1 (ko) 2004-02-05
PL213698B1 (pl) 2013-04-30
US6943192B2 (en) 2005-09-13
ATE257378T1 (de) 2004-01-15
AU4854299A (en) 2000-02-14
CA2336945A1 (en) 2000-02-03
WO2000004894A3 (en) 2000-04-27
AU759278B2 (en) 2003-04-10
KR20030027089A (ko) 2003-04-03
EP1098643A2 (en) 2001-05-16
CN100400039C (zh) 2008-07-09
CN1660061A (zh) 2005-08-31
EA004179B1 (ru) 2004-02-26
DK1098643T3 (da) 2004-05-24
US20010044466A1 (en) 2001-11-22
PL345959A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
CA2336945C (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
KR950002150B1 (ko) 레보도파 메틸에스테르를 함유하는 제약 조성물
KR20120027371A (ko) Ｄｏｐａ 데카르복실라제 억제제의 연속투여용 조성물
KR20040065565A (ko) 세포독성 화학요법의 독성효과 감소에 유용한 아미노산 및리보플라빈 조성물
RU2283105C2 (ru) Аналоги жирных кислот для лечения рака
KR20040063913A (ko) 2-(4-이소부틸페닐)프로피온산의 약학 조성물
US9173889B2 (en) Heparin-based compositions and methods for the inhibition of metastasis
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
CA3133204A1 (en) Drug and method for treating or preventing diabetes complications using same drug
EP0551180B1 (en) Use of bucillamine for the manufacture of a medicament for the treatment of cystinuria
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
US4918193A (en) Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion
US7226766B2 (en) S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
EP1649855A1 (en) Medicinal composition
US20220211821A1 (en) Composition for preventing or treating obesity, comprising phospholipase a2 as active ingredient
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease
LL0S0 et al. PRECLINICAL STUDIES ON ANTINEOPLASTON AS2-1 AND

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190702